Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | CTMX |
---|---|---|
09:32 ET | 5955 | 1.2 |
09:34 ET | 18497 | 1.17 |
09:36 ET | 2148 | 1.199 |
09:38 ET | 24235 | 1.19 |
09:39 ET | 1200 | 1.21 |
09:43 ET | 7108 | 1.215 |
09:45 ET | 300 | 1.22 |
09:48 ET | 15966 | 1.22 |
09:50 ET | 1400 | 1.215 |
09:52 ET | 500 | 1.21 |
09:54 ET | 600 | 1.215 |
09:56 ET | 1000 | 1.22 |
09:57 ET | 900 | 1.22 |
09:59 ET | 198 | 1.22 |
10:01 ET | 500 | 1.22 |
10:03 ET | 50502 | 1.21 |
10:06 ET | 600 | 1.22 |
10:10 ET | 4007 | 1.2165 |
10:12 ET | 10932 | 1.22 |
10:14 ET | 6064 | 1.215 |
10:15 ET | 5737 | 1.22 |
10:17 ET | 3362 | 1.22 |
10:19 ET | 4400 | 1.23 |
10:21 ET | 3000 | 1.225 |
10:26 ET | 1180 | 1.23 |
10:28 ET | 65872 | 1.2499 |
10:30 ET | 114900 | 1.24 |
10:32 ET | 4700 | 1.24 |
10:33 ET | 1227 | 1.24 |
10:35 ET | 53937 | 1.25 |
10:37 ET | 1900 | 1.25 |
10:39 ET | 7477 | 1.2401 |
10:42 ET | 500 | 1.25 |
10:44 ET | 400 | 1.25 |
10:46 ET | 23850 | 1.2488 |
10:48 ET | 48039 | 1.25 |
10:50 ET | 10430 | 1.2504 |
10:51 ET | 5116 | 1.25 |
10:53 ET | 300 | 1.255 |
10:55 ET | 4168 | 1.27 |
10:57 ET | 1089 | 1.2687 |
11:00 ET | 1770 | 1.27 |
11:02 ET | 900 | 1.27 |
11:04 ET | 821 | 1.27 |
11:06 ET | 600 | 1.27 |
11:09 ET | 200 | 1.27 |
11:11 ET | 1758 | 1.27 |
11:13 ET | 7100 | 1.265 |
11:15 ET | 2397 | 1.26 |
11:18 ET | 1050 | 1.2601 |
11:20 ET | 5730 | 1.27 |
11:22 ET | 1582 | 1.27 |
11:24 ET | 1300 | 1.27 |
11:26 ET | 200 | 1.27 |
11:27 ET | 100 | 1.27 |
11:29 ET | 22540 | 1.25 |
11:31 ET | 5100 | 1.245 |
11:33 ET | 584 | 1.24 |
11:36 ET | 835 | 1.25 |
11:38 ET | 1000 | 1.2401 |
11:40 ET | 100 | 1.25 |
11:42 ET | 400 | 1.25 |
11:44 ET | 500 | 1.25 |
11:45 ET | 892 | 1.25 |
11:47 ET | 1300 | 1.25 |
11:49 ET | 400 | 1.25 |
11:51 ET | 400 | 1.25 |
11:54 ET | 1600 | 1.25 |
11:56 ET | 186 | 1.2401 |
11:58 ET | 2600 | 1.25 |
12:05 ET | 1000 | 1.25 |
12:07 ET | 200 | 1.245 |
12:09 ET | 300 | 1.2426 |
12:16 ET | 2529 | 1.24 |
12:23 ET | 600 | 1.25 |
12:25 ET | 100 | 1.24 |
12:27 ET | 100 | 1.245 |
12:30 ET | 600 | 1.25 |
12:32 ET | 300 | 1.25 |
12:34 ET | 100 | 1.25 |
12:36 ET | 200 | 1.25 |
12:38 ET | 100 | 1.24 |
12:41 ET | 200 | 1.24 |
12:45 ET | 800 | 1.25 |
12:56 ET | 8856 | 1.24 |
12:57 ET | 600 | 1.24 |
12:59 ET | 600 | 1.24 |
01:01 ET | 400 | 1.24 |
01:03 ET | 100 | 1.245 |
01:15 ET | 502 | 1.245 |
01:17 ET | 7000 | 1.2402 |
01:21 ET | 100 | 1.241178 |
01:24 ET | 100 | 1.25 |
01:26 ET | 342 | 1.2423 |
01:28 ET | 133 | 1.25 |
01:35 ET | 100 | 1.25 |
01:48 ET | 700 | 1.2403 |
02:04 ET | 400 | 1.24 |
02:06 ET | 200 | 1.245 |
02:11 ET | 400 | 1.24 |
02:13 ET | 5300 | 1.24 |
02:15 ET | 5365 | 1.24 |
02:18 ET | 200 | 1.23 |
02:20 ET | 1400 | 1.23 |
02:22 ET | 1100 | 1.2274 |
02:24 ET | 300 | 1.23 |
02:26 ET | 100 | 1.23 |
02:27 ET | 200 | 1.23 |
02:29 ET | 200 | 1.23 |
02:31 ET | 400 | 1.23 |
02:33 ET | 7019 | 1.22 |
02:38 ET | 5207 | 1.21 |
02:40 ET | 100 | 1.21 |
02:54 ET | 500 | 1.22 |
02:56 ET | 1800 | 1.21 |
02:58 ET | 202 | 1.215 |
03:03 ET | 5000 | 1.2103 |
03:05 ET | 100 | 1.215 |
03:09 ET | 790 | 1.2117 |
03:14 ET | 31095 | 1.2081 |
03:16 ET | 900 | 1.21 |
03:18 ET | 13200 | 1.2 |
03:20 ET | 10881 | 1.2 |
03:21 ET | 44858 | 1.21 |
03:30 ET | 140 | 1.205 |
03:32 ET | 300 | 1.2 |
03:34 ET | 100 | 1.2 |
03:36 ET | 200 | 1.2 |
03:38 ET | 100 | 1.2 |
03:39 ET | 200 | 1.2 |
03:41 ET | 300 | 1.2 |
03:43 ET | 900 | 1.2 |
03:45 ET | 200 | 1.2 |
03:48 ET | 200 | 1.2 |
03:50 ET | 1700 | 1.2 |
03:52 ET | 4580 | 1.2 |
03:54 ET | 200 | 1.2 |
03:56 ET | 200 | 1.2 |
03:57 ET | 1700 | 1.2 |
03:59 ET | 17647 | 1.2 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
CytomX Therapeutics Inc | 96.1M | 8.8x | --- |
Spero Therapeutics Inc | 74.0M | 4.1x | --- |
Aytu Biopharma Inc | 15.4M | -0.9x | --- |
2Seventy Bio Inc | 242.1M | -1.6x | --- |
Fortress Biotech Inc | 44.9M | -0.4x | --- |
Cannabis Bioscience International Holdings Inc | 8.3M | 0.0x | --- |
CytomX Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company focused on developing novel conditionally activated biologics designed to be localized to the tumor microenvironment. It is advancing potential first-in-class and best-in-class antibody-based therapeutics created using its PROBODY therapeutic technology platform. Its pipeline comprises therapeutic candidates across multiple treatment modalities including antibody-drug conjugates (ADCs), T-cell engagers, and immune modulators such as cytokines. Its clinical-stage pipeline includes CX-904, CX-2051 and CX-801. CX-904 is a conditionally activated T-cell-engaging antibody targeting the epidermal growth factor receptor on tumor cells and the CD3 receptor on T cells and partnered with Amgen in a global co-development alliance. CX-2051 is a conditionally activated ADC directed toward epithelial cell adhesion molecule (EpCAM) with potential applicability across multiple EpCAM-expressing epithelial cancers.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $96.1M |
---|---|
Revenue (TTM) | $119.6M |
Shares Outstanding | 78.1M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.04 |
EPS | $0.14 |
Book Value | $-0.70 |
P/E Ratio | 8.8x |
Price/Sales (TTM) | 0.8 |
Price/Cash Flow (TTM) | 7.4x |
Operating Margin | 4.79% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.